5090-16-4Relevant academic research and scientific papers
EZH2 inhibitor as well as preparation of EZH2 inhibitor and application of EZH2 inhibitor in anti-tumor treatment
-
Paragraph 0205; 0207; 0208, (2019/08/20)
The invention discloses an EZH2 inhibitor as well as preparation of the EZH2 inhibitor and application of the EZH2 inhibitor in anti-tumor treatment. The EZH2 inhibitor has a structure represented bya general formula I shown in the description, wherein de
Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists
Saito, Tetsuji,Obitsu, Tetsuo,Kohno, Hiroshi,Sugimoto, Isamu,Matsushita, Takeshi,Nishiyama, Taihei,Hirota, Tomoko,Takeda, Hiroyuki,Matsumura, Naoya,Ueno, Sonoko,Kishi, Akihiro,Kagamiishi, Yoshifumi,Nakai, Hisao,Takaoka, Yoshikazu
experimental part, p. 1122 - 1138 (2012/03/10)
To identify structurally novel corticotropin-releasing factor 1 (CRF 1) receptor antagonists, a series of bicyclic core analogs pyrrolo[1,2-b]pyridazines and pyrrolo[2,1-f]triazin-4(3H)-ones, which were designed based on a monocyclic core antag
